2017_SBRT_Course Book
Trageted Therapy: Described Side effects
Sperduto PW Phase III trial (RTOG 0320) WBRT/SRT
Temozolamid Erlotinib
47% grade ¾ Skin reaction including acne Pneumonia Muscle weakness Myocardial ischemia Brain necrosis
Schulze B
Case reports WBRT
BRAF inhibitor Vermurafenib
Skin toxicity
Kies AP
SRS
Ipilimumab
Symptomatic Radionecrosis
• Targeted therapy in combination with RT can increase side effects • Targeted therapy may have a radiosensitizing effect • Studies have to be performed evaluating side effects
Made with FlippingBook Annual report